One-month regimen of rifapentine + isoniazid non inferior to daily isoniazid for 9 months
A study published March 14, 2019 in the New England Journal of Medicine found that a 1-month regimen of daily rifapentine + isoniazid was noninferior to 9 months of isoniazid alone for preventing tuberculosis in HIV-infected patients. Patients in the 1-month group had a lower incidence of adverse events and were more likely to complete treatment than were those in the 9-month group.
To continue reading this article
Continue reading your article with a eMediNexus account.